Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762614 | 0.74 | LRRK2 (0.33) | — | |
| SCHEMBL21626242 | 0.68 | NLRP3 (0.31) | — | |
| SCHEMBL21525629 | 0.65 | CHEK1 (0.42) | SMN1; SMN2 | |
| SCHEMBL23104465 | 0.63 | DRD4 (0.38) | — | |
| SCHEMBL31493025 | 0.61 | — | — | |
| SCHEMBL23750909 | 0.61 | MPO (0.41) | — | |
| SCHEMBL18338504 | 0.61 | LRRK2 (0.39) | — | |
| SCHEMBL21646647 | 0.60 | MPO (0.38) | SMN1; SMN2 | |
| SCHEMBL9020228 | 0.60 | HDAC4 (0.34) | SMN1; SMN2 | |
| SCHEMBL21626247 | 0.59 | LRRK2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3823974-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112513048-A | Sulfonylimide compounds as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020018975-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2017170765-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2017-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | SMN1; SMN2 1748/4885 |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | SMN1; SMN2 1748/4885 |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | IL1A, IL18, IL1B | SMN1; SMN2 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.